BMS-1001 (hydrochloride)

BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM[1][2].

Product Specifications

CAS Number

[2113650-04-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PD-1/PD-L1

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bms-1001-hydrochloride.html

Concentration

10mM

Purity

98.01

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

OC[C@@H](NCC1=CC(C)=C(C=C1OCC2=CC=CC(C#N)=C2)OCC3=CC=CC(C4=CC=C5OCCOC5=C4)=C3C)C(O)=O.[H]Cl

Molecular Formula

C35H35ClN2O7

Molecular Weight

631.11

Precautions

H302, H315, H319, H335

References & Citations

[1]Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8 (42) :72167-72181.|[2]Guzik K, et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017 Jul 13;60 (13) :5857-5867.